Table 1.
Case summaries of concurrent MOGAD and syphilis infection.
| Publication | Age (y), sex | Neurological diagnosis | MOG-Ig positivity at onset; serum, CSF [titer or MFI ratio] |
Syphilis stage | Co-infections |
|---|---|---|---|---|---|
| Gudenkauf et al., Neuroimmunology Reports. 2021 ( 13) | 31, male | Meningoencephalomyelitis | Positive [1:80], N/A | Latent | None |
| Jeyakumar et al., Neuroimmunology Reports. 2021 ( 14) | 45, male | Papillitis, intermediate uveitis | N/A a , positive | Neurosyphilis | None |
| Shi et al., Front Neurol. 2023 ( 15) | 37, male | Optic neuritis | Positive [1:200], positive [1:200] | Neurosyphilis | None |
| Kulsvehagen et al., Front Immunol. 2024 | 43, male | Cervical myelitis | Positive [14], N/A | Latent | HIV, latent tuberculosis |
| Kulsvehagen et al., Front Immunol. 2024 | 44, male | Optic neuritis | Positive [20], borderline positive [3] | Latent | Hepatitis B |
Summary of five reported patients with coexisting (neuro)syphilis and MOGAD. MOG-IgG titers and MFI ratios were included when available.
CSF, cerebrospinal fluid; MOG, myelin oligodendrocyte glycoprotein; N/A, not available; HIV, human immunodeficiency virus.
a
The serum sample at disease onset was not available (the serum sample collected 2 months after disease onset was MOG-IgG negative).